AIM Financial Statements From 2010 to 2024

Stocks . UK . 
Stock . AIM ImmunoTech
0A4Y Stock   0.23  0.01  4.55%   
AIM ImmunoTech financial statements provide useful quarterly and yearly information to potential AIM ImmunoTech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on AIM ImmunoTech financial statements helps investors assess AIM ImmunoTech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting AIM ImmunoTech's valuation are summarized below:
Gross Profit
-715 K
Revenue
201 K
Earnings Share
(0.40)
Quarterly Revenue Growth
0.19
Revenue Per Share
0.004
There are over fourty-four available fundamental signals for AIM ImmunoTech, which can be analyzed over time and compared to other ratios. All traders should validate AIM ImmunoTech's prevailing fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.

AIM ImmunoTech Total Revenue

191,840

Check AIM ImmunoTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AIM ImmunoTech's main balance sheet or income statement drivers, such as Interest Income of 422.2 K, Interest Expense of 0.0 or Selling General Administrative of 8 M, as well as many indicators such as . AIM financial statements analysis is a perfect complement when working with AIM ImmunoTech Valuation or Volatility modules.
  
This module can also supplement various AIM ImmunoTech Technical models . Check out the analysis of AIM ImmunoTech Correlation against competitors.
For more information on how to buy AIM Stock please use our How to Invest in AIM ImmunoTech guide.

AIM ImmunoTech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets78 M74.3 M35.1 M
Slightly volatile
Total Current Liabilities575.4 K605.7 K2 M
Slightly volatile
Total Stockholder Equity74 M70.5 M30.9 M
Slightly volatile
Cash46.5 M44.3 M15.1 M
Slightly volatile
Other Assets1.1 M1.2 M1.4 M
Slightly volatile
Cash And Short Term Investments47.1 M44.9 M17.5 M
Slightly volatile
Short Term Investments547.3 K576.1 K2.4 M
Slightly volatile
Capital Surpluse374 M462.9 M349.2 M
Slightly volatile
Other Current Assets611.2 K687.6 K748.7 K
Slightly volatile
Total Liabilities6.2 M3.8 M4.3 M
Slightly volatile
Total Current Assets60.6 M57.7 M21.7 M
Slightly volatile
Intangible Assets1.2 M1.7 M1.1 M
Slightly volatile
Common Stock29 K55.2 K28.9 K
Slightly volatile
Property Plant Equipment5.9 M3.8 M7.7 M
Slightly volatile
Short and Long Term Debt Total3.3 M2.2 M2.3 M
Slightly volatile
Other Liabilities29.9 K31.5 K608.4 K
Slightly volatile
Net Tangible Assets65.4 M62.3 M24.9 M
Slightly volatile
Accounts Payable169.3 K178.2 K547.1 K
Slightly volatile
Long Term Debt3.2 M4.5 M2.8 M
Slightly volatile
Net Receivables1 M1.9 M628.9 K
Slightly volatile
Short Term Debt2.7 M3.1 M3.3 M
Slightly volatile

AIM ImmunoTech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income422.2 K521 K302.8 K
Slightly volatile
Selling General Administrative8 M10 M7.8 M
Slightly volatile
Total Revenue191.8 K146.7 K161 K
Slightly volatile
Cost Of Revenue779.8 K725.4 K975.9 K
Slightly volatile

AIM ImmunoTech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock74 M70.4 M25.6 M
Slightly volatile
Depreciation701.3 K697.5 K943.2 K
Slightly volatile
Total Cash From Financing Activities18.2 M9.4 M10.9 M
Slightly volatile

About AIM ImmunoTech Financial Statements

AIM ImmunoTech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although AIM ImmunoTech investors may analyze each financial statement separately, they are all interrelated. The changes in AIM ImmunoTech's assets and liabilities, for example, are also reflected in the revenues and expenses on on AIM ImmunoTech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue146.7 K191.8 K
Cost Of Revenue725.4 K779.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for AIM Stock Analysis

When running AIM ImmunoTech's price analysis, check to measure AIM ImmunoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AIM ImmunoTech is operating at the current time. Most of AIM ImmunoTech's value examination focuses on studying past and present price action to predict the probability of AIM ImmunoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AIM ImmunoTech's price. Additionally, you may evaluate how the addition of AIM ImmunoTech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY